| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Bradykinin B2 Receptor (B2R)
|
|---|---|
| ln Vivo |
Angiotensin III, but not angiotensin II (contraction mediated by the angiotensin AT1 receptor), Lys-des-Arg9-Bradykinin, or des-Arg9-Bradykinin (activity mediated by the bradykinin B1 receptor) are all potentiated by isatin acetate (10–30 μM)[3].
|
| Animal Protocol |
Animal/Disease Models: Female mice of the CBA/J (H-2k) strain[2].
Doses: 0.06, 0.3, or 1.5 mg/kg. Route of Administration: subcutaneous (sc) administration twice (two times) daily. Experimental Results: The length of the large intestine was 93.6± 6.8 mm with the 1.5 mg/kg dosage and 94.0±4.1 mm with the 0.3 mg/kg dosage, showing a significant preventive effect on shortening. |
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation There is currently no information regarding the secretion of atebandin into breast milk. Because atebandin is a protein molecule with a molecular weight of 1305 Da, its concentration in breast milk is likely very low. Furthermore, it is likely to be partially destroyed in the infant's gastrointestinal tract, so the amount absorbed by the infant may be minimal. One patient has been reported to have used this medication safely while breastfeeding. Wait 6 hours after administration before breastfeeding to minimize the amount of medication secreted into breast milk. ◉ Effects on Breastfed Infants A woman with hereditary angioedema began on-demand subcutaneous injections of 30 mg atebandin when her breastfed infant was 4 months old to treat an episode of hereditary angioedema and continued breastfeeding for 1 year while taking atebandin. The dose was administered at night before the infant's longest sleep period, and breastfeeding was resumed at least 6 hours after administration. If facial and neck swelling and abdominal pain occur, immediately self-medicate with itiband and replace breast milk with formula. Two years later, during her second pregnancy, she used a C1 esterase inhibitor until the baby was one month old, after which she resumed itiband treatment. ◉ Effects on breastfeeding and lactation As of the revision date, no relevant published information was found. |
| References |
|
| Additional Infomation |
Itiban acetate is the acetate form of ileban, a human bradykinin B2 receptor (B2R) antagonist used to treat hereditary angioedema (HAE). After administration, ileban targets and binds to B2R, thereby preventing bradykinin from binding to B2R. This may inhibit bradykinin/B2R-mediated vasodilation, thereby reducing vascular permeability and alleviating HAE-related swelling, inflammation, and pain. It may also prevent or improve pulmonary edema unrelated to hereditary angioedema (HAE) and improve associated hypoxemia.
See also: Icariban (containing the active ingredient). Drug Indications Firazyr is indicated for the symptomatic treatment of acute exacerbations of hereditary angioedema (HAE) in adults with C1 esterase inhibitor deficiency. Accord (Icatiban) is indicated for the symptomatic treatment of acute exacerbations of hereditary angioedema (HAE) in adults, adolescents, and children aged 2 years and older (with C1 esterase inhibitor deficiency). Treatment of hereditary angioedema |
| Molecular Formula |
C61H93N19O15S
|
|---|---|
| Molecular Weight |
1364.57
|
| Exact Mass |
1363.68
|
| CAS # |
138614-30-9
|
| Related CAS # |
Icatibant;130308-48-4
|
| PubChem CID |
6918172
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6g/cm3
|
| LogP |
1.676
|
| Hydrogen Bond Donor Count |
16
|
| Hydrogen Bond Acceptor Count |
20
|
| Rotatable Bond Count |
30
|
| Heavy Atom Count |
96
|
| Complexity |
2750
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
CC(=O)O.C1CC[C@H]2[C@@H](C1)C[C@H](N2C(=O)[C@H]3CC4=CC=CC=C4CN3C(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=CS5)NC(=O)CNC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H]7CCCN7C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)N)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O
|
| InChi Key |
HKMZRZUEADSZDQ-DZJWSCHMSA-N
|
| InChi Code |
InChI=1S/C59H89N19O13S.C2H4O2/c60-37(14-5-19-67-57(61)62)48(82)72-38(15-6-20-68-58(63)64)52(86)75-22-8-18-43(75)54(88)77-30-35(80)26-44(77)50(84)70-28-47(81)71-40(27-36-13-9-23-92-36)49(83)74-41(31-79)53(87)76-29-34-12-2-1-10-32(34)24-46(76)55(89)78-42-17-4-3-11-33(42)25-45(78)51(85)73-39(56(90)91)16-7-21-69-59(65)66;1-2(3)4/h1-2,9-10,12-13,23,33,35,37-46,79-80H,3-8,11,14-22,24-31,60H2,(H,70,84)(H,71,81)(H,72,82)(H,73,85)(H,74,83)(H,90,91)(H4,61,62,67)(H4,63,64,68)(H4,65,66,69);1H3,(H,3,4)/t33-,35+,37+,38-,39-,40-,41-,42-,43-,44-,45-,46+;/m0./s1
|
| Chemical Name |
(2S)-2-[[(2S,3aS,7aS)-1-[(3R)-2-[(2S)-2-[[(2S)-2-[[2-[[(2S,4R)-1-[(2S)-1-[(2S)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid;acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (73.28 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7328 mL | 3.6642 mL | 7.3283 mL | |
| 5 mM | 0.1466 mL | 0.7328 mL | 1.4657 mL | |
| 10 mM | 0.0733 mL | 0.3664 mL | 0.7328 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
